ARTICLE | Clinical News

Pheburane regulatory update

October 6, 2014 7:00 AM UTC

The Medunik Canada subsidiary of Le Groupe Pharmaceutique Boivin (Montreal, Quebec) said Health Canada granted Priority Review to a regulatory application for pheburane as adjunctive therapy in the chronic management of urea cycle disorders (UCD). The company has exclusive rights to commercialize Lucane's pheburane in Canada for UCD (see BioCentury, Dec. 16, 2013). ...